Canadian Cancer Trials Group Bulletins


Recent Publication

Results of a study utilizing material from Canadian Cancer Trials Group MA.12, a prospective randomized trial of tamoxifen versus placebo in pre-menopausal women with primary breast cancer, to evaluate the prognostic and predictive significance of intrinsic subtypes identified by both the PAM50 gene set and by immunohistochemistry (IHC) was recently published in Clinical Cancer Research.

Chia SK, Bramwell-Wesley V, Tu D, Shepherd L, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker J, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50 Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen (ONLINE). Clin Cancer Res 2012.